Why some infections never leave: HIV, hepatitis B and TB latency explained

Most infections follow a familiar arc: you catch something, feel ill, the immune system mounts a response, and within days or weeks the pathogen is cleared and you recover, often with lasting immunity. A small but important group of infections breaks that arc. They persist for years or for life, not because the immune system fails to notice them but because the pathogens have evolved specific strategies to avoid being finished off. Three of the most consequential — HIV, tuberculosis, and hepatitis B — persist by three different tricks, and comparing them explains why "chronic infection" is really several distinct problems wearing one name.

HIV: hiding inside the genome

HIV is the starkest case of persistence because of where it hides. As a retrovirus, HIV inserts a DNA copy of its own genes into the DNA of the host's immune cells [s2]. Most infected cells are active and are eventually destroyed, but a fraction become long-lived resting cells that carry the integrated viral genes silently, producing no virus and so presenting nothing for the immune system or drugs to attack — the latent reservoir [s2]. This is the central obstacle to curing HIV. Modern antiretroviral therapy can suppress the actively replicating virus so thoroughly that it becomes undetectable in the blood and untransmittable, but it cannot reach the integrated, silent copies; stop the drugs and the reservoir reawakens and the virus rebounds [s2]. That is why HIV treatment is lifelong and why a true cure — as opposed to control — remains so difficult: you would have to find and eliminate cells that are, by design, indistinguishable from healthy ones [s2].

Tuberculosis: dormant and waiting

Tuberculosis persists differently — not by hiding in the genome but by going dormant. After infection with Mycobacterium tuberculosis, the immune system in most people contains the bacteria rather than eliminating them, walling them off in a state that causes no symptoms and is not contagious. This is latent TB infection, and its scale is enormous: the World Health Organization estimates that about a quarter of the world's population has been infected with TB bacteria [s1]. The great majority never become ill. But the containment is not permanent eradication — the bacteria can persist and later reactivate, and the WHO estimates that people with TB infection have on average a 5-10% lifetime risk of going on to develop active TB disease, with the risk far higher in those whose immune systems are weakened, including by HIV [s1]. That combination — a vast reservoir of latent infection and a lifetime reactivation risk — is why TB remains one of the world's leading infectious killers despite being curable with antibiotics [s1].

Hepatitis B: a persistence set early in life

Hepatitis B shows a third pattern, in which whether an infection becomes chronic depends heavily on when it is acquired. The hepatitis B virus establishes a stable form of its genome inside liver cells that the immune system struggles to clear, and the outcome hinges on the maturity of the immune system at the time of infection [s3]. The WHO describes the striking age gradient: the younger a person is when infected, the more likely the infection is to become lifelong. The risk of chronic infection is greatest in infancy — a large majority of babies infected around birth develop chronic hepatitis B — whereas most healthy adults who are infected clear the virus and recover [s3]. That single fact reshapes prevention: it is why vaccinating newborns, ideally with a dose at birth, is such a high priority, because it blocks infection precisely when it would be most likely to become permanent [s3]. Chronic hepatitis B can be controlled with long-term antiviral treatment that suppresses the virus and reduces liver damage, but as with HIV, suppression is not the same as elimination [s3].

Three strategies, one lesson

The through-line is that chronicity is not a single failure of the immune system but a set of distinct evolutionary solutions to the same problem the pathogen faces — how to avoid being cleared. HIV integrates and goes silent; TB bacteria go dormant behind an immune wall; hepatitis B exploits an immature immune system and lodges in the liver [s1][s2][s3]. This is also why "cure" means different things for each: hepatitis C, by contrast, is now curable with a short drug course, while for HIV and chronic hepatitis B the realistic goal for most patients is durable suppression, and for latent TB it is preventing reactivation. Understanding which strategy a given infection uses is what tells you whether medicine can end it or only hold it in check. This explainer describes the biology of persistent infection; it is not clinical guidance, and anyone affected by these conditions needs individual medical care.